Shareholder Alert: Ademi LLP investigates whether Graphite Bio, Inc. has obtained a Fair Price in its transaction with LENZ Therapeutics

Provided By PR Newswire

Last update: Nov 16, 2023

MILWAUKEE, Nov. 16, 2023 /PRNewswire/ -- Ademi LLP is investigating Graphite Bio (NASDAQ: GRPH) for possible breaches of fiduciary duty and other violations of law in its transaction with LENZ Therapeutics.